Gilead Sciences Statistics
Share Statistics
Gilead Sciences has 1.25B shares outstanding. The number of shares has increased by -0.08% in one year.
| Shares Outstanding | 1.25B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.07% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.24B |
| Failed to Deliver (FTD) Shares | 325 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 17.74M, so 1.42% of the outstanding shares have been sold short.
| Short Interest | 17.74M |
| Short % of Shares Out | 1.42% |
| Short % of Float | 1.43% |
| Short Ratio (days to cover) | 3.5 |
Valuation Ratios
The PE ratio is 17.85 and the forward PE ratio is 12.7. Gilead Sciences 's PEG ratio is 0.47.
| PE Ratio | 17.85 |
| Forward PE | 12.7 |
| PS Ratio | 3.73 |
| Forward PS | 4.1 |
| PB Ratio | 4.43 |
| P/FCF Ratio | 13.62 |
| PEG Ratio | 0.47 |
Enterprise Valuation
Gilead Sciences Inc. has an Enterprise Value (EV) of 120.00B.
| EV / Earnings | 21.18 |
| EV / Sales | 4.43 |
| EV / EBITDA | 11.43 |
| EV / EBIT | 15.78 |
| EV / FCF | 16.17 |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of 1.09.
| Current Ratio | 1.43 |
| Quick Ratio | 1.27 |
| Debt / Equity | 1.09 |
| Total Debt / Capitalization | 52.25 |
| Cash Flow / Debt | 0.32 |
| Interest Coverage | 8.06 |
Financial Efficiency
Return on equity (ROE) is 0.25% and return on capital (ROIC) is 13.03%.
| Return on Equity (ROE) | 0.25% |
| Return on Assets (ROA) | 0.09% |
| Return on Capital (ROIC) | 13.03% |
| Revenue Per Employee | 1.51M |
| Profits Per Employee | 314.72K |
| Employee Count | 18.00K |
| Asset Turnover | 0.44 |
| Inventory Turnover | 3.64 |
Taxes
| Income Tax | 1.25B |
| Effective Tax Rate | 0.18 |
Stock Price Statistics
The stock price has increased by 14.34% in the last 52 weeks. The beta is 0.19, so Gilead Sciences 's price volatility has been higher than the market average.
| Beta | 0.19 |
| 52-Week Price Change | 14.34% |
| 50-Day Moving Average | 89.65 |
| 200-Day Moving Average | 76.41 |
| Relative Strength Index (RSI) | 54.45 |
| Average Volume (20 Days) | 6.78M |
Income Statement
In the last 12 months, Gilead Sciences had revenue of $27.12B and earned $5.67B in profits. Earnings per share was $4.54.
| Revenue | 27.12B |
| Gross Profit | 20.62B |
| Operating Income | 7.61B |
| Net Income | 5.67B |
| EBITDA | 10.50B |
| EBIT | 7.61B |
| Earnings Per Share (EPS) | 4.54 |
Balance Sheet
The company has $6.08B in cash and $24.99B in debt, giving a net cash position of -$18.90B.
| Cash & Cash Equivalents | 6.08B |
| Total Debt | 24.99B |
| Net Cash | -18.90B |
| Retained Earnings | 16.30B |
| Total Assets | 54.52B |
| Working Capital | 3.05B |
Cash Flow
In the last 12 months, operating cash flow was $8.01B and capital expenditures -$585.00M, giving a free cash flow of $7.42B.
| Operating Cash Flow | 8.01B |
| Capital Expenditures | -585.00M |
| Free Cash Flow | 7.42B |
| FCF Per Share | 5.95 |
Margins
Gross margin is 76.04%, with operating and profit margins of 28.05% and 20.89%.
| Gross Margin | 76.04% |
| Operating Margin | 28.05% |
| Pretax Margin | 25.3% |
| Profit Margin | 20.89% |
| EBITDA Margin | 38.71% |
| EBIT Margin | 28.05% |
| FCF Margin | 27.37% |
Dividends & Yields
GILD pays an annual dividend of $3.08, which amounts to a dividend yield of 3.33%.
| Dividend Per Share | $3.08 |
| Dividend Yield | 3.33% |
| Dividend Growth (YoY) | 2.67% |
| Payout Ratio | 3422.22% |
| Earnings Yield | 4.94% |
| FCF Yield | 6.48% |
Analyst Forecast
The average price target for GILD is $96.5, which is 5.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $96.5 |
| Price Target Difference | 5.1% |
| Analyst Consensus | Buy |
| Analyst Count | 24 |
Stock Splits
The last stock split was on Jan 28, 2013. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 2.85 |
| Piotroski F-Score | 8 |